Connie Schmaljohn
Overview
Explore the profile of Connie Schmaljohn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1280
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andrade V, Cashman K, Rosenke K, Wilkinson E, Josleyn N, Lynn G, et al.
Commun Med (Lond)
. 2024 Nov;
4(1):253.
PMID: 39609515
Background: We have previously developed a DNA-based vaccine, INO-4500, encoding the Lassa lineage IV glycoprotein precursor. INO-4500, when delivered with electroporation, elicited humoral and cellular responses, and conferred 100% protection...
2.
Semper A, Olver J, Warner J, Cehovin A, Fay P, Hart P, et al.
Lancet Infect Dis
. 2024 Nov;
PMID: 39522529
Crimean-Congo haemorrhagic fever (CCHF) is a widely distributed and potentially fatal tick-borne viral disease with no licensed specific treatments or vaccines. In 2019, WHO published an advanced draft of a...
3.
Dacon C, Peng L, Lin T, Tucker C, Lee C, Cong Y, et al.
Cell Host Microbe
. 2023 Jun;
31(6):1071-1072.
PMID: 37321165
No abstract available.
4.
Cong Y, Mucker E, Perry D, Dixit S, Kollins E, Byrum R, et al.
Antiviral Res
. 2023 Apr;
213:105589.
PMID: 37003305
The COVID-19 pandemic spurred the rapid development of a range of therapeutic antibody treatments. As part of the US government's COVID-19 therapeutic response, a research team was assembled to support...
5.
Dacon C, Peng L, Lin T, Tucker C, Lee C, Cong Y, et al.
Cell Host Microbe
. 2022 Nov;
31(1):97-111.e12.
PMID: 36347257
Humanity has faced three recent outbreaks of novel betacoronaviruses, emphasizing the need to develop approaches that broadly target coronaviruses. Here, we identify 55 monoclonal antibodies from COVID-19 convalescent donors that...
6.
Dacon C, Tucker C, Peng L, Lee C, Lin T, Yuan M, et al.
Science
. 2022 Jul;
377(6607):728-735.
PMID: 35857439
The potential for future coronavirus outbreaks highlights the need to broadly target this group of pathogens. We used an epitope-agnostic approach to identify six monoclonal antibodies that bind to spike...
7.
Monteil V, Eaton B, Postnikova E, Murphy M, Braunsfeld B, Crozier I, et al.
EMBO Mol Med
. 2022 Jul;
14(8):e15230.
PMID: 35781796
The recent emergence of multiple SARS-CoV-2 variants has caused considerable concern due to both reduced vaccine efficacy and escape from neutralizing antibody therapeutics. It is, therefore, paramount to develop therapeutic...
8.
Dacon C, Tucker C, Peng L, Lee C, Lin T, Yuan M, et al.
bioRxiv
. 2022 Apr;
PMID: 35441178
One-sentence Summary: Rare monoclonal antibodies from COVID-19 convalescent individuals broadly neutralize coronaviruses by targeting the fusion peptide.
9.
Cho H, Gonzales-Wartz K, Huang D, Yuan M, Peterson M, Liang J, et al.
Sci Transl Med
. 2021 Sep;
13(616):eabj5413.
PMID: 34519517
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern threatens the efficacy of existing vaccines and therapeutic antibodies and underscores the need for additional antibody-based tools...
10.
Cho H, Gonzales-Wartz K, Huang D, Yuan M, Peterson M, Liang J, et al.
bioRxiv
. 2021 Apr;
PMID: 33821267
The emergence of SARS-CoV-2 variants that threaten the efficacy of existing vaccines and therapeutic antibodies underscores the urgent need for new antibody-based tools that potently neutralize variants by targeting multiple...